USD10
ADPT Shares
About Adaptive BiotechnologiesAdaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
USD10
ADPT Shares
About Adaptive BiotechnologiesAdaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.91B
OPEN PRICE
$13.84
LOW (1Y)
$6.26
HIGH (1Y)
$20.76
LOW (24H)
$12.02
HIGH (24H)
$13.86
VOLUME (24H)
$4.95M
306.25%
Price history
Time | Price | Change |
|---|---|---|
Today | $13.84 | |
1 Day | $13.73 | |
1 Week | $13.58 | |
1 Month | $15.91 | |
1 Year | $7.43 |